These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 3192681

  • 1. Serum aminoterminal propeptide of type III procollagen: a potential predictor of the response to growth hormone therapy.
    Tapanainen P, Risteli L, Knip M, Käär ML, Risteli J.
    J Clin Endocrinol Metab; 1988 Dec; 67(6):1244-9. PubMed ID: 3192681
    [Abstract] [Full Text] [Related]

  • 2. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
    Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, DiNero G.
    Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
    [Abstract] [Full Text] [Related]

  • 3. Long-term monitoring of treatment with recombinant human growth hormone by serial determinations of type III procollagen-related antigens in serum.
    Danne T, Grüters A, Schnabel K, Burger W, L'Allemand D, Enders I, Helge H, Weber B.
    Pediatr Res; 1988 Feb; 23(2):167-71. PubMed ID: 3353159
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Serum levels of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen in children with growth retardation.
    Cinaz P, Hasanoglu E, Gökçora N, Dogukan S, Demir A.
    Mater Med Pol; 1994 Feb; 26(2):55-8. PubMed ID: 7745984
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature.
    Gascoin-Lachambre G, Trivin C, Brauner R, Souberbielle JC.
    Growth Horm IGF Res; 2007 Jun; 17(3):194-200. PubMed ID: 17321775
    [Abstract] [Full Text] [Related]

  • 8. Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.
    Sartorio A, Arosio M, Conti A, Ferrero S, Porretti S, Faglia G.
    J Endocrinol Invest; 1999 Mar; 22(3):169-75. PubMed ID: 10219883
    [Abstract] [Full Text] [Related]

  • 9. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
    Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G.
    J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
    [Abstract] [Full Text] [Related]

  • 10. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy.
    Tobiume H, Kanzaki S, Hida S, Ono T, Moriwake T, Yamauchi S, Tanaka H, Seino Y.
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2056-61. PubMed ID: 9215272
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.
    Sartorio A, Conte G, Conti A, Masala A, Alagna S, Rovasio P, Faglia G.
    J Endocrinol Invest; 2000 Jun; 23(6):356-61. PubMed ID: 10908162
    [Abstract] [Full Text] [Related]

  • 14. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy.
    Kubo T, Tanaka H, Inoue M, Kanzaki S, Seino Y.
    Bone; 1995 Oct; 17(4):397-401. PubMed ID: 8573414
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Renal handling of phosphate can predict height velocity during growth hormone therapy for short children.
    Nishiyama S, Ikuta M, Nakamura T, Tomoeda S, Matsuda I.
    J Clin Endocrinol Metab; 1992 Apr; 74(4):906-9. PubMed ID: 1548358
    [Abstract] [Full Text] [Related]

  • 19. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [Abstract] [Full Text] [Related]

  • 20. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI, Juustila H, Pyhtinen J, Jokinen K, Alavaikko M, Ruokonen A.
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.